InflaRx NV Company Insiders
| IFRX Stock | USD 2.36 0.05 2.16% |
InflaRx NV employs about 62 people. The company is managed by 15 executives with a total tenure of roughly 145 years, averaging almost 9.0 years of service per executive, having 4.13 employees per reported executive. Break down of InflaRx NV's management performance can provide insight into the company performance.
InflaRx |
InflaRx NV Management Team Effectiveness
The company has return on total asset (ROA) of (0.2198) % which means that it has lost $0.2198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4534) %, meaning that it created substantial loss on money invested by shareholders. InflaRx NV's management efficiency ratios could be used to measure how well InflaRx NV manages its routine affairs as well as how well it operates its assets and liabilities.InflaRx NV Workforce Comparison
InflaRx NV is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,792. InflaRx NV holds roughly 62.0 in number of employees claiming about 3% of equities under Health Care industry.
InflaRx NV Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. InflaRx NV Price Series Summation is a cross summation of InflaRx NV price series and its benchmark/peer.
InflaRx NV Notable Stakeholders
An InflaRx NV stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as InflaRx NV often face trade-offs trying to please all of them. InflaRx NV's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting InflaRx NV's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jan CFA | Head VP | Profile | |
| Petra Esser | VP Controlling | Profile | |
| Thomas Taapken | Chief Officer | Profile | |
| Derval OCarroll | Senior Compliance | Profile | |
| Igor Orshanskiy | Senior Development | Profile | |
| Maria Habel | Head RD | Profile | |
| Christian Schmid | VP Counsel | Profile | |
| Kofi Boaten | Senior Supplies | Profile | |
| Bruce Burnett | VP Affairs | Profile | |
| Pr MD | Chief CoFounder | Profile | |
| Camilla MD | Chief Officer | Profile | |
| Evelyn RothGeissler | VP Operations | Profile | |
| Nicole Bertsch | Senior Resources | Profile | |
| Kafi Boaten | Director Supplies | Profile | |
| Peter Hurt | Director Pharmacovigiliance | Profile |
About InflaRx NV Management Performance
The success or failure of an entity such as InflaRx NV often depends on how effective the management is. InflaRx NV management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of InflaRx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the InflaRx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Fireman BV is traded on NASDAQ Exchange in the United States.
Please note, the imprecision that can be found in InflaRx NV's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of InflaRx NV. Check InflaRx NV's Beneish M Score to see the likelihood of InflaRx NV's management manipulating its earnings.
InflaRx NV Workforce Analysis
Traditionally, organizations such as InflaRx NV use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare InflaRx NV within its industry.InflaRx NV Manpower Efficiency
Return on InflaRx NV Manpower
| Revenue Per Employee | 1K | |
| Revenue Per Executive | 4.2K | |
| Net Loss Per Employee | 688.2K | |
| Net Loss Per Executive | 2.8M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 6.2M |
Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.